Teriparatide in the management of osteoporosis.
Teriparatide in the management of osteoporosis.
复制标题
DOI：
10.2147/cia.s241
复制
发表时间：
2007
影响因子：
3.6
通讯作者：
Riggs A
中科院分区：
文献类型：
--
作者：
Bodenner D;Redman C;Riggs A
髋关节骨折是老年人常见的灾难性事件，通常导致患者在一年内死亡，幸存者中很少有人能恢复骨折前的生活质量。虽然不太被认识到，但脊柱骨折导致显著的发病率，并且与没有骨折的个体相比还与死亡率增加相关。近年来，用于治疗骨质疏松症的新药的开发出现了爆炸式增长。重组人甲状旁腺激素（1-34）（20 μg/天）是最近添加到这一医疗设备中的新的作用机制，于2002年11月被美国FDA批准用于治疗绝经后骨质疏松症和继发于性腺功能减退的男性骨质疏松症。它是第一种骨质疏松症治疗方法，可导致新骨形成，其结构与正常骨相似。已经做出了大量的努力来了解特立帕肽对抗吸收治疗的作用，反之亦然。虽然这些关系还没有完全理解，但最近的研究结果使临床医生开始优化骨矿物质密度的治疗增益并提高抗骨折疗效。
Fracture of the hip is frequently a catastrophic event in the elderly, often resulting in death within a year and of the survivors, few regain pre-fracture quality of life. Although less appreciated, fractures of the spine result in significant morbidity and are also associated with increased mortality compared with individuals without a fracture. In recent years there has been an explosion in the development of new drugs for the treatment of osteoporosis. Recombinant human parathyroid hormone (1–34) (20 μg/day) is a recent addition to this armamentarium with a novel mechanism of action, which was approved by the US FDA for the treatment of post-menopausal osteoporosis and male osteoporosis secondary to hypogonadism in November 2002. It is the first osteoporosis treatment that leads to the formation of new bone with architecture similar to normal bone. Intense efforts have been made to understand the effect of teriparatide on antiresorptive therapy and vice versa. Although these relationships are not completely understood, the results of recent studies allow clinicians to begin to optimize therapeutic gains in bone mineral density and improve anti-fracture efficacy.